HB 411 Maryland Department of Health Reports on Standing Orders and Opioid Overdose Reversal Drugs

About HB-411

Requiring the Maryland Department of Health to report to certain committees of the General Assembly on current opioid overdose reversal drugs and, for any current opioid overdose reversal drug approved by the federal Food and Drug Administration, whether the Department has added the drug to a standing order and, if not, the reasons why the drug has not been added; and requiring the report to be submitted by December 1, 2024, December 1, 2025, and December 1, 2026.